Timber Pharmaceuticals — Investor Presentation (February 2021)
22 slides from Timber Pharmaceuticals's investor presentation, Feb 4, 2021
Slide 1: Building Bridges in Medical Dermatology
Building Bridges in Medical Dermatology Investor Presentation NYSE American: TMBR February 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward - looking s
Slide 3: Timber Pharmaceuticals Overview
3 Timber Pharmaceuticals Overview Timber Pharmaceuticals is building a rare and orphan dermatology company that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company’s investigational thera
Slide 4: Investment Highlights
4 Investment Highlights • Positioned to become a leading dermatology company with a focus on rare and orphan diseases, led by a management team with a pro ven track record in development and commercialization • High potential, late stage, lower risk multi - product candidate pipeline • Proven clinic
Slide 5: Timber's Focused Strategy and Tactics
5 Timber’s Focused Strategy and Tactics • Focus on mitigating the cost, risk, and time of drug development while retaining earnings potential • Based on three key tactics: • Emphasis on compounds with broad and proven mechanisms of action across many dermatologic conditions • Differentiation of the
Slide 6: Timber Business Model
6 Timber Business Model • Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Why Orphan Drugs? • Timber will be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires smaller and less costly drug trials with greater flexibility
Slide 7: Rare dermatological diseases underrepresented in drug development
7 • Rare dermatological diseases are underrepresented in drug development and pharmaceutical company sponsored trials • Approximately 30 million people in the U.S. are living with a rare disease – equivalent to 1 in 10 Americans • Many orphan and rare dermatology disorders are associated with signif
Slide 8: Strategic Pipeline in Rare Dermatologic Disease
8 Strategic Pipeline in Rare Dermatologic Disease NYSE American: TMBR SP4
Slide 9: TMB-001 for Congenital Ichthyosis
9 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis has a prevalence of 1:2,000 - 1:6,000 males • Lamellar Ichthyosis has a prevalence of 1:100,000 - 200,000 Quality of life is signif
Slide 10: TMB-001 Topical Isotretinoin in CI
10 Isotretinoin is widely viewed as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where high dose, chronic oral therapy cannot be tolerated due to systemic toxicity TMB - 001 utilizes patented IPEG™ delivery system to target isotretino
Slide 11: TMB-002 for Facial Angiofibromas in Tuberous Sclerosis Complex
11 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple
Slide 12: TMB-002 Topical Rapamycin (Pascomer)
12 TMB - 002 Topical Rapamycin (Pascomer®) Potentially the First Commercially Available, High - Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in preclinical toxicity studies Utilizes tr
Slide 13: Barriers to Entry
13 Barriers to Entry • Orphan exclusivity granted for all three strategic assets • 7 years in U.S., 10 years in E.U. • Patents granted and pending globally • Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidation, temperature sensitivities, stab
Slide 14: TMB-003 Topical Sitaxsentan for Cutaneous Fibrosis
14 TMB - 003 Topical Sitaxsentan for Cutaneous Fibrosis Highly Selective ET - A inhibitor Sitaxsentan was a highly selective (6,500:1) ET - A receptor antagonist previously on the market in the EU, Canada and Australia as an oral treatment for PAH, but voluntarily withdrawn from global market in 201
Slide 15: Scleroderma
15 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in the U.S. • Systemic s
Slide 16: Life Cycle Management
16 Life Cycle Management Market expansion potential for additional indications for all products Severe Acne Port Wine Stains Hypertrophic/Keloid Scars TMB - 001 TMB - 002 TMB - 003 Sturge - Weber Syndrome Darier’s Disease Scarring Alopecia Sebaceous Hyperplasia NYSE American: TMBR Rare Diseases High
Slide 17: Significant Clinical Milestones over next 12 months
17 Significant Clinical Milestones on a Quarterly Basis over next 12 months TMB - 001 TMB - 002 Q1 2021 Reach 50% enrollment of the Phase 2B trial Reach 50% enrollment of the Phase 2B trial Q2 2021 Complete enrollment Complete enrollment Receive 3 rd tranche of grant funding Q3 2021 Topline data for
Slide 18: World Class Clinical Advisors and Partners
18 World Class Clinical Advisors and Partners Clinical Advisors • Peter Elias, MD – Professor, Dept of Dermatology, University of California, San Francisco (UCSF) • Keith Choate, MD, PhD – Professor of Dermatology, Pathology, and Genetics, Yale University • Joyce Teng, MD – Professor and Director of
Slide 19: Leadership Team
19 Leadership Team Strong Balance between Entrepreneurial Acumen and Proven Operational Leadership Michael Derby, MS, MBA Executive Chairman • Pharma entrepreneur with several successful exits • Managing Partner of TardiMed Sciences • Founder of Norphan Pharmaceuticals, rare neurology drug developme
Slide 20: Financial and Capitalization Highlights
20 Financial and Capitalization Highlights On May 18, 2020, upon closing of its merger with a NYSE - listed company, Timber also completed a financing with gross proceeds of $25 million, which included the conversion of a $5 million bridge note previously issued by Timber and the issuance of Series
Slide 21: Investment summary
21 ▪ Topical Isotretinoin for Congenital Ichthyosis ▪ Topical Rapamycin for Facial Angiofibromas in Tuberous Sclerosis Complex ▪ Locally Delivered Endothelin - A Antagonist for Scleroderma ▪ Partnering opportunities for recently acquired non - strategic Topical Minocycline programs ▪ Track record of
Slide 22: Building Bridges in Medical Dermatology - Contact
Building Bridges in Medical Dermatology For additional Investor Information please contact: John Koconis Stephanie Prince CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 Thank You www.timberpharma.com
Timber Pharmaceuticals — Investor Presentation (February 2021) on 6ix